A 59-year-old man with nonalcoholic steatohepatitis was found to have a 12.4-cm liver mass, with imaging characteristics concerning for malignant neoplasm (Figure, A). A biopsy was performed, and pathology results were consistent with a well-differentiated hepatocellular carcinoma. He enrolled in a phase 1 clinical trial (NCT03299946) using neoadjuvant cabozantinib plus nivolumab followed by definitive resection for patients with locally advanced disease.
Shah PP, Romo CG, Yarchoan M. Weakness and Myalgia in a Patient With Hepatocellular Carcinoma Undergoing Checkpoint Inhibitor Therapy. JAMA Oncol. Published online August 29, 2019. doi:10.1001/jamaoncol.2019.2304
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: